Cargando…
Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
Objective: While several drugs have been linked to acute pancreatitis (AP), the AP-related risk of most drugs remains unclear. This study investigated the risk factors for drug-induced AP by analyzing a large dataset from the FDA Adverse Event Reporting System (FAERS). Methods: The reporting odds ra...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690789/ https://www.ncbi.nlm.nih.gov/pubmed/38044938 http://dx.doi.org/10.3389/fphar.2023.1231320 |
_version_ | 1785152596805156864 |
---|---|
author | Zhang, Lin Mao, Wei Liu, Dan Hu, Bin Lin, Xiaofang Ran, Jie Li, Xingxing Hu, Jing |
author_facet | Zhang, Lin Mao, Wei Liu, Dan Hu, Bin Lin, Xiaofang Ran, Jie Li, Xingxing Hu, Jing |
author_sort | Zhang, Lin |
collection | PubMed |
description | Objective: While several drugs have been linked to acute pancreatitis (AP), the AP-related risk of most drugs remains unclear. This study investigated the risk factors for drug-induced AP by analyzing a large dataset from the FDA Adverse Event Reporting System (FAERS). Methods: The reporting odds ratios (ROR) were used to assess the reports of drug-induced AP from the first quarter of 2004 to the second quarter of 2022. Single-factor, LASSO, and multi-factor regression analysis were performed to explore drug-related AP-related risk factors. Bonferroni correction was applied for the multiple comparisons performed. Results: A total of 264 drugs associated with AP, including antineoplastic drugs (35/264), antidiabetic drugs (28/264), antibacterial drugs (24/264), immunomodulatory drugs (11/264), antipsychotic drugs (6/264), and other drugs (160/264) were retrieved. Multi-factor analysis showed that males, age 41–54 years old, and 36 drugs, including Tigecycline, were risk factors for drug-related AP. The median time to drug-related AP onset was 31 days (interquartile range [IQR] 7–102 days) and about 75% of adverse events occurred within 100 days. Conclusion: These findings may help clinicians to identify drug-related AP at the early stage and can be used to inform future studies of drug-related AP pathogenesis. |
format | Online Article Text |
id | pubmed-10690789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106907892023-12-02 Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS) Zhang, Lin Mao, Wei Liu, Dan Hu, Bin Lin, Xiaofang Ran, Jie Li, Xingxing Hu, Jing Front Pharmacol Pharmacology Objective: While several drugs have been linked to acute pancreatitis (AP), the AP-related risk of most drugs remains unclear. This study investigated the risk factors for drug-induced AP by analyzing a large dataset from the FDA Adverse Event Reporting System (FAERS). Methods: The reporting odds ratios (ROR) were used to assess the reports of drug-induced AP from the first quarter of 2004 to the second quarter of 2022. Single-factor, LASSO, and multi-factor regression analysis were performed to explore drug-related AP-related risk factors. Bonferroni correction was applied for the multiple comparisons performed. Results: A total of 264 drugs associated with AP, including antineoplastic drugs (35/264), antidiabetic drugs (28/264), antibacterial drugs (24/264), immunomodulatory drugs (11/264), antipsychotic drugs (6/264), and other drugs (160/264) were retrieved. Multi-factor analysis showed that males, age 41–54 years old, and 36 drugs, including Tigecycline, were risk factors for drug-related AP. The median time to drug-related AP onset was 31 days (interquartile range [IQR] 7–102 days) and about 75% of adverse events occurred within 100 days. Conclusion: These findings may help clinicians to identify drug-related AP at the early stage and can be used to inform future studies of drug-related AP pathogenesis. Frontiers Media S.A. 2023-11-17 /pmc/articles/PMC10690789/ /pubmed/38044938 http://dx.doi.org/10.3389/fphar.2023.1231320 Text en Copyright © 2023 Zhang, Mao, Liu, Hu, Lin, Ran, Li and Hu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Lin Mao, Wei Liu, Dan Hu, Bin Lin, Xiaofang Ran, Jie Li, Xingxing Hu, Jing Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS) |
title | Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS) |
title_full | Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS) |
title_fullStr | Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS) |
title_full_unstemmed | Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS) |
title_short | Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS) |
title_sort | risk factors for drug-related acute pancreatitis: an analysis of the fda adverse event reporting system (faers) |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690789/ https://www.ncbi.nlm.nih.gov/pubmed/38044938 http://dx.doi.org/10.3389/fphar.2023.1231320 |
work_keys_str_mv | AT zhanglin riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers AT maowei riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers AT liudan riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers AT hubin riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers AT linxiaofang riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers AT ranjie riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers AT lixingxing riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers AT hujing riskfactorsfordrugrelatedacutepancreatitisananalysisofthefdaadverseeventreportingsystemfaers |